**Diagnostic Cascade Quality Indicators**

These indicators should be monitored and analysed by the supervisory laboratory or by the national programme semi-annually or annually. Testing sites should be able to provide some of the data needed to assess the quality of the diagnostic cascade. Some of the indicators will also need data from clinicians and programme personnel, which may be collected routinely or using a once or twice a year survey depending on the country capacity. (See XXX for Excel data collection tool template).

|  |
| --- |
| Site Name |
| District |
| Name of person compiling this report |
| Reporting period (Month/Year) |

|  |  |  |  |
| --- | --- | --- | --- |
| **Total Numbers** | | | |
| Number of presumptive TB patients tested with Xpert MTB/RIF | A |  | |
| Number of presumptive TB patients | B |  | |
| Number of notified new and relapse TB cases tested with a WRD as the initial diagnostic test | C |  | |
| Number of notified new and relapse TB cases | D |  | |
| Number of notified new and relapse TB cases with bacteriological confirmation | E |  | |
| Number of bacteriologically confirmed patients who were initiated on treatment according to the national algorithm | F |  | |
| Number of bacteriologically confirmed patients identified | G |  | |
| Number of testing sites using a WRD at which a data system has been established that transmits results electronically to clinicians and to an information management system | H |  | |
| Number of testing sites using a WRD | I |  | |
| Number of Xpert MTB/RIF test results reported to clinicians using electronic systems | J |  | |
| Number of Xpert MTB/RIF test results reported to clinicians | K |  | |
| Number of TB patients detected by Xpert MTB/RIF that were reported to the TB control program, or TB focal person | L |  |
| Number of TB patients detected by Xpert MTB/RIF | M |  | |
| Number of notified bacteriologically confirmed TB cases with DST results for rifampicin | N |  | |
| Number of notified rifampicin-resistant TB cases with DST results for fluoroquinolones and second-line injectable agent | O |  | |
| Number of notified rifampicin-resistant TB cases | P |  | |
| Number of patients with RIF-resistant TB identified by Xpert MTB/RIF testing referred for second-line DST | Q |  | |
| Number of patients with RIF-resistant TB identified by Xpert MTB/RIF testing | R |  | |
| Number of specimens collected for Xpert MTB/RIF testing for which a test result was received within the specified time | S |  | |
| Number of specimens collected for Xpert MTB/RIF testing for which a result was returned | T |  | |
| Number of referred specimens for which a test result was received within the specified time | U |  | |
| Number of specimens referred for which a result was returned | V |  | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Analysis** | | | |
| **Indicator** | **Formula** | **Result** | **Target** |
| [% presumptive TB patients tested with Xpert MTB/RIF (Indicator 1 of Framework)](file:///C:\Users\Thomas\Desktop\FIND%202018\Indicator%20forms%20and%20calculations.xlsx#RANGE!_ftn1) | [A/B]x100 |  | Dependent on population tested and TB prevalence |
| % notified new and relapse TB cases tested with a WRD as the initial diagnostic test (Indicator 2 of Framework) | [C/D]x100 |  | 80% (2020) |
| % notified new and relapse TB cases with bacteriological confirmation (Indicator 3 of Framework) | [E/D]x100 |  | 80% [relapse: 90%] (2020) |
| % bacteriologically confirmed patients who were initiated on treatment according to the national algorithm | [F/G]x100 |  | Target is setting specific |
| % testing sites using a WRD at which a data connectivity system transmits results electronically to clinicians and to an information management system (Indicator 4 of Framework) | [H/I]x100 |  | 100% (2020) |
| % Xpert MTB/RIF test results reported to clinicians using electronic systems | [J/K]x100 |  | Target is setting specific |
| % TB patients detected by Xpert MTB/RIF that were reported to the TB control program, TB or MDR TB treatment focal person | [L/M]x100 |  | Target is setting specific |
| % notified bacteriologically confirmed TB cases with DST results for rifampicin (Indicator 7 of Framework) | [ /D]x100 |  | 100% (2020) |
| % notified RIF-resistant TB cases with DST results for fluoroquinolones and SLIDs (Indicator 8 of Framework) | [O/P]x100 |  | 100% (2020) |
| % patients with RIF-resistant TB identified by Xpert MTB/RIF testing referred for second-line DST | [Q/R]x100 |  | 100% |
| % specimens for which an Xpert result was received within the specified target time (i.e., time from collection to receipt of results) | [S/T]x100 |  | >95%. The ‘specified time’ should be determined for each laboratory |
| % specimens referred for DST for which a result was received within the specified target time (i.e.*,* time from referral of a specimen to receipt of results) | [U/V]x100 |  | >95%. The ‘specified time’ should be determined for each laboratory |